ArticleJournal of clinical microbiology2016
In Vitro Antimicrobial Susceptibility of Staphylococcus pseudintermedius Isolates of Human and Animal Origin.
Article in Journal of clinical microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Comparative Phenotypic and PCR-Based Methicillin Resistance Characterization of Clinical CanineAntibiotics (Basel, Switzerland) · 2026Article
- Veterinary method evaluation of Vitek-2 compact for antimicrobial susceptibility testing ofJournal of clinical microbiology · 2026Article
- Comparative Susceptibility of Pathogenic Methicillin-Resistant and Methicillin-SusceptibleLife (Basel, Switzerland) · 2023Article
- Does Nitrofurantoin Improve the Portfolio of Vets against Resistant Bacteria in Companion Animals?Antibiotics (Basel, Switzerland) · 2023Review
- Staphylococcal species composition in the skin microbiota of domestic pigeons (Columba livia domestica).PloS one · 2023Article
- Prevalence, Mechanism, Genetic Diversity, and Cross-Resistance Patterns of Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2022Article
- From canines to humans: Clinical importance of Staphylococcus pseudintermedius.PLoS pathogens · 2021Article
- Antimicrobial Prodrug Activation by the Staphylococcal Glyoxalase GloB.ACS infectious diseases · 2020Article
- Potent, specific MEPicides for treatment of zoonotic staphylococci.PLoS pathogens · 2020Article
- Performance of Five Commercial Identification Platforms for Identification of Staphylococcus delphini.Journal of clinical microbiology · 2019Article
- Epidemiology, Clinical Characteristics, and Antimicrobial Susceptibility Profiles of Human Clinical Isolates of Staphylococcus intermedius Group.Journal of clinical microbiology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MIC results for 115 Staphylococcus intermedius group isolates are presented. Of these, 33% were methicillin resistant, among which 51.4% were susceptible to doxycycline, 29.7% to clindamycin, and 21.6% to trimethoprim-sulfamethoxazole. All of the isolates were susceptible to ceftaroline, daptomycin, linezolid, nitrofurantoin, quinupristin-dalfopristin, rifampin, tigecycline, and vancomycin. Of all the isolates, 82.6%, 67.8%, and 23.5% were susceptible to ciprofloxacin, erythromycin, and penicillin, respectively. No isolates harbored mupA or qacA/B genes, which suggested a lack of resistance to mupirocin or chlorhexidine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.